Circular RNAs-mediated angiogenesis in human cancers
© 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO)..
Circular RNAs (circRNAs) as small non-coding RNAs with cell, tissue, or organ-specific expression accomplish a broad array of functions in physiological and pathological processes such as cancer development. Angiogenesis, a complicated multistep process driving a formation of new blood vessels, speeds up tumor progression by supplying nutrients as well as energy. Abnormal expression of circRNAs reported to affect tumor development through impressing angiogenesis. Such impacts are introduced as constant with different tumorigenic features known as "hallmarks of cancer". In addition, deregulated circRNAs show possibilities to prognosis and diagnosis both in the prophecy of prognosis in malignancies and also their prejudice from healthy individuals. In the present review article, we have evaluated the angiogenic impacts and anti-angiogenic managements of circRNAs in human cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 25(2023), 11 vom: 11. Nov., Seite 3101-3121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghaedrahmati, Farhoodeh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis |
|---|
| Anmerkungen: |
Date Completed 22.09.2023 Date Revised 22.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12094-023-03178-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355444348 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355444348 | ||
| 003 | DE-627 | ||
| 005 | 20231226064346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-023-03178-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355444348 | ||
| 035 | |a (NLM)37039938 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghaedrahmati, Farhoodeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circular RNAs-mediated angiogenesis in human cancers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2023 | ||
| 500 | |a Date Revised 22.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO). | ||
| 520 | |a Circular RNAs (circRNAs) as small non-coding RNAs with cell, tissue, or organ-specific expression accomplish a broad array of functions in physiological and pathological processes such as cancer development. Angiogenesis, a complicated multistep process driving a formation of new blood vessels, speeds up tumor progression by supplying nutrients as well as energy. Abnormal expression of circRNAs reported to affect tumor development through impressing angiogenesis. Such impacts are introduced as constant with different tumorigenic features known as "hallmarks of cancer". In addition, deregulated circRNAs show possibilities to prognosis and diagnosis both in the prophecy of prognosis in malignancies and also their prejudice from healthy individuals. In the present review article, we have evaluated the angiogenic impacts and anti-angiogenic managements of circRNAs in human cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Tumorigenesis | |
| 650 | 4 | |a circRNAs | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 700 | 1 | |a Nasrolahi, Ava |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi, Sajad |e verfasserin |4 aut | |
| 700 | 1 | |a Mighani, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Anbiyaee, Omid |e verfasserin |4 aut | |
| 700 | 1 | |a Haybar, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Assareh, Ahmad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Kempisty, Bartosz |e verfasserin |4 aut | |
| 700 | 1 | |a Dzięgiel, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Azizidoost, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Farzaneh, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico |d 2005 |g 25(2023), 11 vom: 11. Nov., Seite 3101-3121 |w (DE-627)NLM155341065 |x 1699-3055 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:11 |g day:11 |g month:11 |g pages:3101-3121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12094-023-03178-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 11 |b 11 |c 11 |h 3101-3121 | ||